Teva Pharmaceutical Industries Limited

Assia Chemical Industries Ltd.

Teva Pharmaceuticals International Gmbh

Teva Pharmaceuticals Usa, Inc.

Ariel Mittelman

Rotem Sella-Erez

Tamar Nidam

Sharona Shachan-Tov

Nurit Perlman

Doron Rudik

Ido Fuchs

Alexander Mainfeld

Yifat Ronen

Motti Erlich

Sharona Shachantov

Nada Kosutic Hulita

Nina Finkelstein

Gideon Pilarski

Maytal Piran

Sigalit Levi

Yuval Cohen

Leonid Metsger

Jonathan Enav

Revital Ramaty

Slavik Yurkovski

Marina Yarovoy

Einat Kisin-Finfer

Luna Ben-Sahel Katzav

Marina Kalujny

Yoav Kowalski

Meital Cohen

Leonid Levenfeld

Idit Tzanani

Elana Ben Moha-Lerman

Sagit Azran

Victoria Machtey

Abed Masarwa

Rotem Sella-erez

Disclosed are solid state forms of lumateperone ditosylate, uses thereof, and pharmaceutical compositions thereof.

Solid state forms of lumateperone ditosylate salt

Solid state forms of Valbenazine, Valbenazine salts, processes for preparation thereof and pharmaceutical compositions thereof are disclosed. Processes for the preparation of Valbenazine and intermediates in the preparation thereof are further described.

Solid state forms of valbenazine

Disclosed are solid state forms of Netarsudil mesylate, processes for preparation thereof, uses thereof, and pharmaceutical compositions thereof.

Solid state forms of netarsudil mesylate

The present invention encompasses solid state forms of Ibrutinib, including forms G, J and K, and pharmaceutical compositions thereof.

Solid state forms of ibrutinib

Solid state forms of Sitagliptin salts (e.g. Sitagliptin sulfate, Formula I), processes for preparing the solid state forms, and pharmaceutical compositions thereof, are provided. These compounds are of a class of dipeptidyl peptidase IV enzyme inhibitors which are useful, for example, for the manufacture of a medicament for the treatment of type 2 diabetes mellitus. 

Solid state forms of sitagliptin salts

The present invention provides novel polymorphs of lapatinib ditosylate, processes for preparing them, and pharmaceutical compositions comprising one or more of these polymorphs.

Forms of lapatinib ditosylate and processes for preparation thereof

Crystalline forms of Sitagliptin salts, processes for preparing crystalline forms of Sitagliptin salts, and pharmaceutical compositions of Sitagliptin salts are provided.

The invention relates to solid states of pharmaceutically acceptable compounds of aliskiren, and processes for preparation thereof. The invention further provides pharmaceutical formulations comprising the amorphous or crystalline forms of pharmaceutically acceptable compounds of aliskiren and processes thereof; and a method of inhibiting renin for treating hypertension.

Solid state forms of aliskiren compounds

Atorvastatin potassium crystalline Forms A, B, E, F, and G are provided. Also provided are methods of preparing atorvastatin potassium crystalline Forms A, B, E, F, and G. Atorvastatin potassium crystalline Forms A, B, E, F, and G may be used to prepare pharmaceutical compositions useful for the treatment of hypercholesterolemia or hyperlipidemia.

Solid states of atorvastatin potassium

Growing community of inventors

Elad, Israel

Ariel Mittelman